Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IXICO to Present at 10th Annual CNS Summit 2019

30 Oct 2019 09:00

RNS Number : 5364R
IXICO plc
30 October 2019
 

30 October 2019

 

IXICO plc

("IXICO" or the "Company")

 

IXICO to Present at 10th Annual CNS Summit 2019

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October to 3rd November 2019 in Boca Raton, Florida, USA.

10th Annual CNS Summit 

31st October - 3rd November 2019, Boca Raton Resort, Florida, USA

 

Robin Wolz, Senior Vice President of Science & Innovation at IXICO will present a poster entitled "Automated sleep-wake prediction from wearable sensors using neural networks - from data collection to algorithm development, cross-validation and clinical trial deployment" during the evening receptions on Friday 1st and Saturday 2nd November 2019.

This study shows how AI technology improved the analysis of sleep/wake accelerometry from wearables compared to traditional, count-based measurements in a robust and reproducible way. Thus, the exploratory use of this validated algorithm in clinical trials is feasible and provides the collection of evidence needed to support further development of real-world evidence in clinical trial designs. 

The rise in people using connected wearable devices has opened the door for the medical field to harness real-time patient health data to support clinical development of many diseases including Alzheimer's and Parkinson's disease.

Founded by R&D leaders, the CNS Summit is a platform of industry leaders working collaboratively to shape the future of the life sciences with a focus on innovation and technology. The agenda features top leaders from the regulators, pharmaceutical and biotech companies, technology and services companies driving change in the healthcare sector.

Poster authors:

Robin Wolz1,2, Luis Peraza1, Richard Joules1, Yves Dauvilliers3

Affiliations: 1- IXICO, London, UK, 2- Imperial College London, London, UK, 3- Department Neurology, Centre Hospitalier Universitaire, Montpellier, France

 

For further information please contact:

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

 

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus

 

IXICO@optimumcomms.com

 

 

About IXICO

 

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

 

More information is available on www.IXICO.com

 

About CNS Summit

 

CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs. CNS Summit believes this mission is its ethical duty to the patients they serve by developing new treatments.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABRBDGXXDBGCC
Date   Source Headline
24th Apr 20157:00 amRNSNew contract in Huntington's disease
11th Mar 20157:00 amRNSVirtualScopics, IXICO and Micron in collaboration
6th Mar 201511:38 amRNSResult of AGM
10th Feb 20154:25 pmRNSReplacement - Financial Results
10th Feb 20157:00 amRNSResults for the 16 month period ended 30 Sept 2014
16th Jan 20157:00 amRNSIXICO selected as EPAD imaging analysis partner
16th Dec 20147:00 amRNSLicense of TrialTracker to VirtualScopics
26th Nov 20147:00 amRNSAnnouncement of enhanced contracts
29th Oct 20147:30 amRNSGrant of Awards to Directors
17th Sep 20147:00 amRNSAppointment of Chief Financial Officer
7th Aug 20147:00 amRNSAdditional Listing
31st Jul 20144:19 pmRNSHolding(s) in Company
21st Jul 20144:33 pmRNSDirector/PDMR Shareholding
18th Jul 20147:00 amRNSTrading Update
19th Jun 20147:00 amRNSCollaboration with the MRC for dementia research
6th Jun 20147:00 amRNSHalf Yearly Report
22nd May 20147:00 amRNSTwo contracts in Huntington's disease awarded
30th Apr 20142:58 pmRNSHolding(s) in Company
16th Apr 20147:00 amRNSIXICO plc announces SBRI Healthcare contract
20th Mar 201412:41 pmRNSResults of AGM
11th Mar 20142:43 pmRNSDirector/PDMR Shareholding
11th Mar 201410:04 amRNSHolding(s) in Company
7th Mar 20142:35 pmRNSInternational alliance with VirtualScopics
28th Feb 20147:00 amRNSPublication of annual report and business update
6th Feb 20147:00 amRNSAppointment of Joint Broker
13th Jan 20149:51 amRNSPresents at Dementia Challenge seminar in Beijing
2nd Jan 20145:08 pmRNSHolding(s) in Company
17th Dec 20137:00 amRNSBusiness and trading update
13th Dec 20137:00 amRNSTSB Grant to Develop Dementia Diagnosis Products
11th Dec 20137:00 amRNSDementia diagnosis tool launch and InHealth update
10th Dec 20137:00 amRNSAttending G8 Global CEO Initiative on Alzheimer's
2nd Dec 201310:03 amRNSIXICO signs MOU with Beijing UMP
18th Nov 20136:00 pmRNSDirector/PDMR Shareholding
1st Nov 20134:01 pmRNSDirector/PDMR Shareholding
31st Oct 201311:26 amRNSDirector/PDMR Shareholding
22nd Oct 201312:29 pmRNSHolding(s) in Company
21st Oct 20131:22 pmRNSDirector/PDMR Shareholding
17th Oct 20133:08 pmRNSHolding(s) in Company
15th Oct 20137:00 amRNSFirst Day of Dealings
14th Oct 201312:18 pmRNSResult of General Meeting
14th Oct 201311:08 amRNSSchedule 1 update - Phytopharm Plc
11th Oct 20131:48 pmRNSSch 1 Update - Phytopharm plc
3rd Oct 20139:23 amRNSHolding(s) in Company
1st Oct 20137:00 amRNSDirector/PDMR Shareholding
30th Sep 20132:45 pmRNSSchedule 1 - Phytopharm Plc
27th Sep 20133:17 pmRNSDirector/PDMR Shareholding
24th Sep 20137:30 amRNSRestoration - Phytopharm Plc
23rd Sep 20137:05 amRNSIXICO expands into digital healthcare
23rd Sep 20137:00 amRNSProposed acquisition of IXICO Limited
29th Aug 201312:01 pmRNSSchedule 1 update - Phytopharm plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.